M&A activity increased among larger systems in 2nd quarter

Thirty-one partnership transactions among hospitals and health systems were announced in the second quarter of 2017, and 58 have been announced so far this year, according to an analysis on merger and acquisition (M&A) activity by Skokie, Ill.-based consulting firm Kaufman Hall.

The 2017 activity is an increase over the first half of 2016, when 52 transactions were announced. The second quarter also included six deals involving healthcare organizations with more than $1 billion in revenue. Recently announced mega-deals included the $2 billion merger between Steward Health and IASIS Healthcare, which would create the largest for-profit hospital operator in the U.S.

"As the field of potential partners evolves, leaders of many larger health systems are thinking strategically about how best to build the scale and capabilities needed to remain competitive in a rapidly changing healthcare environment," said Patrick Allen, a managing director at Kaufman Hall. "Traditional providers face an array of uncertainties, from changing federal healthcare policies to shifting payment and care delivery models. Health systems across the country are looking to grow and transform their operations to ensure stability in the face of turbulent times."

Eight transactions involved for-profit acquirers, 22 involved not-for-profit acquirers and one was a for-profit/not-for-profit combination. Pennsylvania and Texas were the sites of the most activity, with four announced transactions each in the second quarter. Tennessee-based Community Health Systems was involved in four transactions, the most of any single company.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.